Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Open in API
Filings indexed 585 across all filing types
Latest filing 2016-12-22 M&A Activity
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
8-K
M&A Activity Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated December 21, 2016, by Tokai Pharmaceuticals, Inc. It details the entry into a material definitive agreement, specifically a Share Purchase Agreement for the acquisition of Otic Pharma, Ltd. The report includes descriptions of the transaction terms, voting proposals, support agreements, and related financing commitments. It also references the forthcoming filing of a definitive proxy statement on Schedule 14A related to the transaction. The content focuses on merger and acquisition activity, including changes in control and stock issuance related to the transaction. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. The document is not a proxy solicitation itself but references the upcoming proxy statement. Given the detailed description of the merger transaction and related agreements, the filing best fits the category of M&A Activity (TAR).
2016-12-22 English
FORM 10-Q
Interim / Quarterly Report Q3 2016
2016-11-03 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The key content is the resignation of a board member, Timothy J. Barberich, effective immediately. This is an announcement of a change in the company's board of directors. The document does not contain financial data or detailed reports but focuses on management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and specific to management changes, confirming this classification.
2016-10-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the discontinuation of a clinical trial and updates on the company's drug development program, which is typical for a current report rather than a full financial report. The document is relatively short (4225 characters) and does not contain financial statements or detailed financial analysis. It is not an earnings release, annual report, or interim report. It is also not a certification or voting result announcement. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-08-22 English
FORM 10-Q
Interim / Quarterly Report Q2 2016
2016-08-04 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes a workforce reduction plan and changes in senior management, specifically the departure of certain officers and the appointment of a new Chief Financial Officer. These details pertain to changes in the company's board of directors or senior management. There is no indication that this is a full annual or quarterly report, audit report, earnings release, or other types of filings. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length (6927 characters) and detailed management changes support this classification with high confidence.
2016-08-03 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.